SRX246
Phase 2Small molecule
SRX246 is one of 8 small molecule programs targeting Aggressive Behavior. It is currently in Phase 2.
1
Indications
7
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Aggressive Behavior
#DrugCompanyPhaseTrials
1Trileptal
NovartisApproved
Versed
CConrado Roberto Hoffmann Filho
Approved
Abilify
OtsukaApproved
Risperdal
WWim Janssens
Approved
Haldol
DDePuy Orthopaedics
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Rexulti
OtsukaPreclinical
SRX246
AAzevan Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Intermittent Explosive Disorder1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SRX246. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAzevan Pharmaceuticals